Hepatitis C virus (HCV) is an enveloped positive-strand RNA virus in the family Flaviviridae with high mutation rate in the genome. Chronic infection causes chronic hepatitis, necrosis and fi brosis, which can progress to cirrhosis and hepatocellular carcinoma which is one of the biggest public heath problem. However, there is no effective vaccine update. The development of HCV vaccine is based on the evaluation of the specifi c immune responses against HCV and protection after challenge.
[1]Lindenbach B, Rice C.Unraveling hepatitis C virus replication from genome to function[J].Nature, 2005, 436 (7053) :933-938.
|
[2]Lavanchy D, Purcell R, Hollinger FB, et al.Global surveillance and control of hepatitis C[J].Viral Hepat, 1999, 6 (1) :35-47.
|
[3]De Francesco R, Migliaccio G.Challenges and succ-esses in developing new therapies for hepatitis C[J].Nature, 2005, 436 (7053) :953-960.
|
[4]Lauer GM, Walker BD.Hepatitis C Virus Infection[J].N Engl J Med, 2001, 345 (1) :41-52.
|
[5]Thimme R, Oldach D, Chang KM, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].Exp Med, 2001, 194 (10) :1395-1406.
|
[6]Cooper S, Erickson AL, Adams EJ, et al.Analysis of a successful immune response against hepatitis C virus[J].Immunity, 1999, 10 (4) :439-449.
|
[7]Lechner F, Wong D, Dunbar P, et al.Analysis of successful immune responses in persons infected with hepatitis C virus[J].J Exp Med, 2000, 191 (9) :1499-1512.
|
[8]Cox A, Mosbruger T, Lauer G, et al.Comprehensive analyses of CD8+T cell responses during longitudinal study of acute human hepatitis C[J].Hepatology, 2005, 42 (1) :104-112.
|
[9]Lechner, F.Gruener N, Urbani S, et al.CD8+T lymphocyte responses are included during acute hepatitis C rirus infection but are not sustained[J].Eur J Immunol, 2000, 30 (9) :2 479-2487.
|
[10]Bassett S, Guerra B, Brasky K, et al.Protective im-mune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection[J].Hepatology, 2001, 33 (6) :1479-1487.
|
[11]Lanford, R, Guerra B, Chavez D, et al.Cross-genotype immunity to hepatitis C virus[J].J Virol, 2004, 78 (3) :1575-1581.
|
[12]Thimme R, Oldach D, Chang K, et al.Determinants of viral clearance and persistence during acute hepatitis C virus infection[J].J Exp Med, 2001, 194 (10) :1395-1406.
|
[13]Shoukry N, Cawthon A, Walker C.Cell-mediated im-munity and the outcome of hepatitis C virus infection[J].Annu Rev Microbiol, 2004, 58:391-424
|
[14]Ulsenheimer A, Gerlach J, Gruener N, et al.Detection of functionally altered hepatitis C virus-specific CD4+T cells in acute and chronic hepatitis C[J].Hepatology, 2003, 37 (5) :1189-1198
|
[15]Wedemeyer H, He X, Nascimbeni M, et al.Impaired effector function of hepatitis C virus-speci-c CD8+T cells in chronic hepatitis C virus Infection[J].J Immunol, 2002, 169 (6) :3447-3458.
|
[16]Appay V, Dunbar P, Callan M, et al.Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections[J].Nat Med, 2002, 8 (4) :379-385.
|
[17]Choo Q, Kuo G, Ralston R, et al.Vaccination of chi-mpanzees against infection by the hepatitis C virus[J].Proc Natl Acad Sci, 1994, 91 (4) :1294-1298.
|
[18]Farci P, Shimoda A, Wong D, et al.Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein[J].Proc Natl Acad Sci, 1996, 93 (26) :15394-15399.
|
[19]Grakoui A, Shoukry N, Woollard D, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
|
[20]Thimme R, Bukh J, Spangenberg H, et al.Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease[J].Proc Natl Acad Sci, 2002, 99 (24) :15661-15668.
|
[21]Folgori A, Capone S, Ruggeri L, et al.A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees[J].Nat Med, 2006, 12 (2) :190-197.
|
[22]Grakoui A, Shoukry NH, Woollard DJ, et al.HCV persistence and immune evasion in the absence of memory T cell help[J].Science, 2003, 302 (5645) :659-662.
|
[23]Neumann C, Thimme R.Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection[J].Genes Immun, 2007, 8 (3) :181-192.
|
[24]Houghton M, Abrignani S.Prospects for a vaccine against the hepatitis C virus[J].Nature, 2005, 436 (7053) :961-966.
|
[25]Rosa D, Campagnoli S, Moretto C, et al.A quantitative test to estimate neutralizing antibodies to the hepatitis C virus:cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells[J].Proc Natl Acad Sci, 1996, 93 (5) :1759-1763.
|
[26]Bartosch B, Dubuisson J, Cosset F.Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1-E2 Envelope Protein Complexes[J].J Exp Med, 2003, 197 (5) :633-642.
|
[27]Wakita T, Pietschmann T, Kato T, et al.Production of临床肝胆病杂志2011年第27卷第1期infectious hepatitis C virus in tissue culture from a cloned viral genome[J].Nat Med, 2005, 11 (7) :791-796.
|
[28]Lindenbach B, Evans M, Syder A, et al.Complete replication of hepatitis C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
|
[29]Stamataki Z, Coates S, Evans M, et al.Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies[J].Vaccine, 2007, 25 (45) :7773-7784.
|
[30]Kreher C, Dittrich M, Guerkov R, et al.CD4+and CD8+cells in cryopreserved human PBMC maintain full functionality in cytokine C virus in cell culture[J].Science, 2005, 309 (5734) :623-626.
|
[31]Diepolder H, Zachoval R, Hoffmann R, et al.Possible mechanism involving T lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection[J].Lancet, 1995, 346 (8981) :1 006-1007.
|
[32]Rigopoulou E, Suri D, Chokshi S, et al.Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B:antiviral and immunological activity[J].Hepatology, 2005, 42 (5) :1028-1036.
|
[33]Elmowalid G, Qiao M, Jeong S, et al.Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees[J].Proc Natl Acad Sci, 2007, 104 (20) :8427-8432.
|
[34]Murata K, Lechmann M, Ming Q, et al.Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection[J].Proc Natl Acad Sci, 2003, 100 (11) :6753-6758
|
[35]Simon B, Cornell K, Clark T, et al.DNA Vaccination Protects Mice against Challenge with Listeria monocytogenes Expressing the Hepatitis C Virus NS3 Protein[J].Infect Immun, 2003, 71 (11) :6372-6380.
|
[36]Encke J, Findeklee J, Geib J, et al.Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection[J].Clin Exp Immunol, 2005, 142 (2) :362-369.
|
[1] | Hongxia LI, Yimeng SUN, Hongtao ZHANG, Shuwang HAN, Delin ZHANG, Haitao SHANG, Wu GUO, Junjian LIU, Zhonglian LI. Role of HBV DNA polymerase in mediating the immune escape of tumor cells in HBV-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(12): 2858-2866. doi: 10.3969/j.issn.1001-5256.2023.12.017 |
[2] | Zhen ZhiJun. A study on optimizing reporting process for hepatitis C virus antibody test for blood donors in blood center′ laboratory [J]. Journal of Clinical Hepatology, 2015, 31(8): 1275-1277. doi: 10.3969/j.issn.1001-5256.2015.08.022 |
[4] | Ma HongBo, Lang ZhenWei, Huang DeZhuang, Yan HuiPing, Luo ChaoXia. Study on transfusion transmitted virus in liver tissue of people with no viral hepatitis by the method of in situ hybridization.[J]. Journal of Clinical Hepatology, 2004, 20(5): 277-278+321. |
[7] | Jiao JianZhong, Liu WangGuo, Li AiYue, Jiao JianXin, Qiu YingFeng, Shen Xu. Clinical Study on Serology of TT Virus Infection and Pathogenicity in Lanzhou[J]. Journal of Clinical Hepatology, 2001, 17(1): 47-48. |
[8] | Wu LongRen, Han XueJi, Cui WeiZhe, Yin MingShi, Po HongXin, Tai YongRi. TTV tvirus infection among 45 cases of hepatitis B and C patients in yan bian city[J]. Journal of Clinical Hepatology, 2000, 16(4): 249-250. |
[9] | Tan XinCheng, Wang Yun, Zhang XiCheng, Liu ZhiHua, Li XiaoPing, Wang LeNong. The clinical characters of Transfusion transmitted virus positive hepatitis patients[J]. Journal of Clinical Hepatology, 2000, 16(4): 234-235. |
[11] | Wu XiaoMan, Guo HaiBo, Lie HaiTao. The quantitative and qualitative PCR detection and clinical application of HBV-DNA[J]. Journal of Clinical Hepatology, 2000, 16(4): 226-227. |
[12] | Wang ZhaoQuan, Shu Bo, Li Ying, Li ZhiWei, Wang JingYan, Wang Mei, Hong Ming, Jin GuoXian, Zhi YaQing. Detection of TTV Incidence Among Difeerent Types of Viral Hepatitis[J]. Journal of Clinical Hepatology, 2000, 16(4): 239-241. |